Platinum(IV) complexes as inhibitors of CD47-SIRPα axis for chemoimmunotherapy of cancer.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of medicinal chemistry"
DOI: 10.1016/j.ejmech.2021.114047
Abstract: Phagocytosis of cancer cells by antigen presenting cells (APCs) is critical to activate the host's immune responses. However, the targeting ability of APCs to cancer cells is limited by the upregulation of transmembrane protein CD47… read more here.
Keywords: cancer; cancer cells; cd47 sirp; platinum complexes ... See more keywords
Recent Advances of Tumor Therapy Based on the CD47-SIRPα Axis.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.2c00073
Abstract: Cancer is still a major disease that is currently difficult for humans to overcome. When the expression of the cluster of differentiation 47 (CD47) is upregulated, tumor cells interact with the macrophage inhibitory receptor signal… read more here.
Keywords: advances tumor; therapy; cd47; cd47 sirp ... See more keywords
2-Amino-1,3,4-thiadiazoles as Glutaminyl Cyclases Inhibitors Increase Phagocytosis through Modification of CD47-SIRPα Checkpoint.
Sign Up to like & getrecommendations! Published in 2022 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.2c00256
Abstract: Glutaminyl cyclases (QC, isoQC) convert N-terminal glutamine or glutamate into pyroglutamate (pGlu) on substrates. IsoQC has recently been demonstrated to promote pGlu formation on the N-terminus of CD47, the SIRPα binding site, contributing to the… read more here.
Keywords: modification; glutaminyl cyclases; cd47; cd47 sirp ... See more keywords
Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2020.1685976
Abstract: Macrophages are often the most abundant immune cell found in the tumor microenvironment, but are frequently associated with poor patient prognosis and considered detrimental to mounting an effectiv... read more here.
Keywords: sirp axis; blockade cd47; axis promising; promising approach ... See more keywords
Enhancement of EGFR antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/SIRPα interactions.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer science"
DOI: 10.1111/cas.14999
Abstract: Integrin associated protein (CD47) is an important target in immunotherapy, as it is expressed as a 'don't eat me' signal on many tumor cells. Interference with its counter molecule signal regulatory protein alpha (SIRPα), expressed… read more here.
Keywords: glutaminyl cyclase; egfr; antibody; inhibition ... See more keywords
Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Immunology"
DOI: 10.1111/imm.13498
Abstract: Tumour therapy has entered the era of immunotherapy. Monoclonal antibodies (mAb), immune checkpoint inhibitors, chimeric antigen receptor T‐cell (CAR‐T), cytokine‐induced killer (CIK), tumour‐infiltrating lymphocytes (TILs) and other cellular immunotherapies have become the focus of current… read more here.
Keywords: immunotherapy; cd47 based; cd47 sirp; based bispecific ... See more keywords
LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-004452
Abstract: Background Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed… read more here.
Keywords: lrig2 promotes; progression; gbm; lrig2 ... See more keywords
Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-122940
Abstract: Background:Apolizumab (APO) is a humanized IgG1 antibody targeting a HLA-DRβ chain specific epitope, which is expressed by approx. 50 % of B cell lymphomas. The antibody's clinical development was hampered by toxicity, potentially mediated by… read more here.
Keywords: lymphoma; cell; sirp interactions; cd47 sirp ... See more keywords
CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.899068
Abstract: Immunotherapies targeting the “don’t eat me” myeloid checkpoint constituted by CD47 SIRPα interaction have promising clinical potential but are limited by toxicities associated with the destruction of non-tumor cells. These dose-limiting toxicities demonstrate the need… read more here.
Keywords: combination trogocytosis; cd47 sirp; anti cd47; cd47 ... See more keywords
Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14071801
Abstract: Simple Summary Cancer cells escape macrophage phagocytosis by exploiting the CD47/SIRPα axis. We found that extensive membranous CD47 expression by cancer cells characterized 29/98 cases. SIRPα and CD68 were expressed by tumor-associated macrophages (Μφ, TAMs).… read more here.
Keywords: cancer; expression; cd47 sirp; cancer cells ... See more keywords
CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14081930
Abstract: Simple Summary Immunotherapies offer broad potential to treat many diseases, including cancer. Macrophages are highly abundant immune cells, but are generally inhibited from eliminating tumor cells by ‘self’ signaling. Blocking this macrophage signaling checkpoint with… read more here.
Keywords: checkpoint; cd47 sirp; tumor; macrophage ... See more keywords